Correlation of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) and Retinoid X Receptor-α (RXR-α) expression with clinical risk factors in patients with advanced carotid atherosclerosis

Constantinos Giaginis1,2, Christos Klonaris3, Athanasios Katsargyris3, Gregorios Kouraklis2, Chara Spiliopoulou1, Stamatios Theocharis1

1 Department of Forensic Medicine and Toxicology, University of Athens, Athens, Greece
2 2nd Department of Propedeutic Surgery, Medical School, University of Athens, Athens, Greece
3 1st Department of Surgery, Medical School, University of Athens, Athens, Greece

Source of support: Constantinos Giaginis was financially supported by a post-doctorate scholarship from the State Scholarship Foundation (I.K.Y.) of the Ministry of Education of Greece

Summary

Background:

Peroxisome proliferator-activated receptor-γ (PPAR-γ) and its nuclear partners, the Retinoid X Receptors (RXRs), have been recognized as crucial players in the pathogenesis of atherosclerosis. The present study aimed to assess the clinical significance of PPAR-γ and RXR-α expression in different cellular populations localized within advanced carotid atherosclerosis lesions.

Material/Methods:

PPAR-γ and RXR-α expression was assessed by immunohistochemistry in 134 carotid atherosclerotic plaques obtained from an equal number of patients that underwent endarterectomy procedure for vascular repair, and was correlated with patients’ medical history, risk factors and medication intake.

Results:

Increased incidence of low PPAR-γ expression in both macrophages and smooth muscle cells was noted in patients presenting coronary artery disease (p=0.032 and p=0.046, respectively). PPAR-γ expression in smooth muscle cells was borderline down-regulated in symptomatic compared to asymptomatic patients (p=0.061), reaching statistical significance when analyzing groups of patients with specific cerebrovascular events; amaurosis fugax (p=0.008), amaurosis fugax/stroke (p=0.020) or amaurosis fugax/transient ischemic attack patients (p=0.028) compared to asymptomatic patients. Low RXR-α expression in macrophages was more frequently observed in hypertensive (p=0.048) and hyperlipidemic patients (p=0.049). Increased incidence of low RXR-α expression in smooth muscle cells was also noted in patients presenting advanced carotid stenosis grade (p=0.015).

Conclusions:

PPAR-γ and RXR-α expression down-regulation in macrophages and smooth muscle cells was associated with a more pronounced disease progression in patients with advanced carotid atherosclerotic lesions.

Key words: carotid atherosclerosis • immunohistochemistry • macrophages • PPAR-γ • RXR-α • smooth muscle cells
BACKGROUND

Atherosclerosis and its complications, such as myocardial infarction and stroke, are the leading cause of morbidity and mortality in the developed world [1]. Stress, tobacco smoking, alcohol consumption, hypertension, diabetes mellitus, obesity, insulin resistance and dyslipidemia have been identified as important risk factors predisposing to atherosclerosis [2,3]. At an early stage of disease, endothelial cells dysfunction causes the release of vasoactive molecules, which stimulate inflammatory responses and recruitment/migration of leukocytes into the arterial wall [4]. Macrophage stimulation leads to the secretion of cytokines, growth factors and other mediators, which promote smooth muscle cell proliferation and migration [5]. In later stages, smooth muscle cells activation stimulates the release of pro-inflammatory cytokines, which, combined with the secretion of matrix metalloproteinases (MMPs) and procoagulant factors, results in chronic inflammatory state and plaque instability [5,6]. The resulting chronic inflammatory state and the enrichment of lipid-laden macrophages (foam cells) contribute to the development of advanced atherosclerotic lesions, which ultimately causes luminal obstruction and plaque rupture, leading to thrombus formation and, eventually, ischemic events [6]. The multi-factorial nature of atherosclerosis involves chronic inflammation at every step from initiation to progression, suggesting that certain clinical risk factors may contribute to the pathogenesis of disease by aggravating the underlying inflammatory process [7].

PPAR-γ is a ligand-activated transcription factor, which belongs to the nuclear receptor superfamily [8]. Upon ligand activation, PPAR-γ forms heterodimers with its nuclear receptor partners, Retinoid X Receptors (RXRs) and binds to specific PPAR response elements (PPREs) in the promoter region of the target genes, regulating gene function through dissociation of co-repressors and recruitment of co-activators [9,10]. RXRs are common heterodimerization partners for several nuclear receptors beyond PPARs, including thyroid receptors (TRs), vitamin D receptor (VDR), and liver, farnesoid and pregnane X receptors (LXR, FXR and PXR, respectively) [11]. The RXR family includes 3 distinct subtypes, termed as RXRα, β and γ; however, it still remains unclear whether their nuclear partners, such as PPAR-γ, exhibit a marked preference for 1 of them [12,13]. Moreover, it has not yet been elucidated whether their role is restricted to acting as heterodimerization partners for nuclear receptors, or if there is actually a separate RXR-mediated signalling pathway [12,13].

Currently, PPAR-γ constitutes a key regulator of glucose homeostasis and adipogenesis and is a promising therapeutic target for the treatment of patients with type 2 diabetes mellitus [14,15]. Two synthetic PPAR-γ activators, pioglitazone and rosiglitazone, which belong to the thiazolidinedione (TZD) class, have successfully been introduced in the market as oral antidiabetic agents to attenuate insulin resistance associated with obesity, hypertension and impaired glucose homeostasis [16,17]. Pleiotropic functions beyond this limit, such as anti-proliferative and anti-inflammatory effects against several pathophysiological states, including neoplasia, ischemia/reperfusion injury, gestational diseases and arthritis, are currently being explored in clinical studies [18–23]. An increasing body of evidence from preclinical and clinical studies has further supported that PPAR-γ ligands, and especially TZDs, exert a broad spectrum of anti-inflammatory and anti-proliferative effects on all cell types participating in the development of cardiovascular diseases [24–26]. Importantly, PPAR-γ was shown to be expressed in atherosclerotic lesions and in all vascular wall apparent cell types [27–30]. PPAR-γ ligand treatment was also reported to attenuate the development and progression of atherosclerotic lesions in several animal models [24,31–34]. Moreover, TZDs treatment was shown to reduce carotid artery intima/media thickness in patients with type 2 diabetes [24,30,35].

Taking into consideration the extensive use of PPAR-γ agonists in patients at high risk for cardiovascular diseases, the understanding of PPAR-γ function in the vasculature is not only of basic interest, but also carries important clinical implications. However, there is no comprehensive research so far concerning the clinical significance of PPAR-γ and its nuclear partner, RXR-α, in patients with advanced carotid atherosclerotic lesions. In view of the above considerations, our study aimed to assess the immunohistochemical expression of PPAR-γ and RXR-α in different cellular populations (macrophages, smooth muscle cells and endothelial cells), localized within advanced atherosclerotic lesions in patients that underwent carotid endarterectomy for vascular repair. Correlations of this differential cellular expression of PPAR-γ and RXR-α with patients’ medical history, risk factors and medication intake were examined.

MATERIAL AND METHODS

Clinical material

One hundred thirty-four (134) consecutive patients of Greek ethnicity that underwent carotid endarterectomy in Laikon Hospital between January 2006 and December 2008 were eligible for this study. The study was approved by the Hospital Ethics Committee, and informed consent was obtained from all participants. Indication for surgery was a symptomatic carotid stenosis ≥50% or an asymptomatic carotid stenosis ≥70% according to ESVS guidelines [36]. Preoperatively, patients had either carotid duplex ultrasound scans or digital subtraction angiograms, or both of these. Patients or plaques were defined as symptomatic when focal symptoms of cerebral ischemia were present, ipsilateral to the carotid lesions, such as transient ischemic attack (TIA), amaurosis fugax, or stroke, in the last 6 months. All patients were preoperatively on antiplatelet treatment that was interrupted 1 week before surgery.

A complete medical history, risk factors and medication intake were recorded, including: age, sex, coronary artery disease-CAD (angina pectoris, myocardial infarction and coronary artery bypass grafting/percutaneous transluminal coronary angioplasty/CABG/PTCA), diabetes mellitus (controlled with diet, oral hypoglycemic agents or insulin; fasting glucose level ≥126mg/dL), hypercholesterolemia (total cholesterol ≥200mg/dL), hypertension (systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or self-report of high blood pressure) [37], peripheral artery disease (PAD), smoking history, and therapy with statins and angiotensin-converting enzyme (ACE) inhibitors. The demographic characteristics of the study population are summarized in Tables 1 and 2.
### Table 1. Associations of PPAR-γ expression in macrophages and smooth muscle cells with medical history, risk factors and medication intake in patients with advanced carotid atherosclerosis lesions.

| Clinical variables | N=134 | PPAR-γ expression in macrophages | PPAR-γ expression in smooth muscle cells |
|--------------------|-------|----------------------------------|----------------------------------------|
|                    |       | Low (%) | High (%) | p-value | Low (%) | High (%) | p-value |
| Age (mean ±SD)     | 71.02±7.98 | 69(51) | 65 (49) | 0.683 | 70 (52) | 64 (48) | 0.103 |
| Gender             |       | 0.617   |          |         | 0.617   |          |         |
| Male               | 109 (81) | 55 (41) | 54 (40) | 0.58 (43) | 51 (38) | 0.51 (38) | 0.51 (38) |
| Female             | 25 (19) | 14 (10) | 11 (8) | 0.51 (9) | 13 (10) | 0.51 (10) | 0.51 (10) |
| Carotid            |       | 0.630   |          |         | 0.630   |          |         |
| Right              | 75 (56) | 40 (30) | 35 (26) | 0.37 (28) | 38 (28) | 0.27 (28) | 0.27 (28) |
| Left               | 59 (44) | 29 (22) | 30 (22) | 0.33 (25) | 26 (19) | 0.33 (25) | 0.33 (25) |
| Stenosis grade     |       | 0.862   |          |         | 0.999   |          |         |
| <90%               | 67 (50) | 34 (25) | 33 (25) | 0.35 (26) | 32 (24) | 0.32 (24) | 0.32 (24) |
| ≥90%               | 67 (50) | 35 (26) | 32 (24) | 0.35 (26) | 32 (24) | 0.32 (24) | 0.32 (24) |
| Diabetes           |       | 0.684   |          |         | 0.898   |          |         |
| No                 | 97 (72) | 51 (38) | 46 (34) | 0.51 (38) | 46 (34) | 0.51 (38) | 0.51 (38) |
| Yes                | 37 (28) | 18 (13) | 19 (14) | 0.19 (14) | 18 (13) | 0.18 (13) | 0.18 (13) |
| Hyperlipidemia     |       | 0.328   |          |         | 0.464   |          |         |
| No                 | 44 (33) | 20 (15) | 24 (18) | 0.21 (16) | 23 (17) | 0.22 (17) | 0.22 (17) |
| Yes                | 90 (67) | 49 (37) | 41 (31) | 0.49 (37) | 41 (31) | 0.41 (31) | 0.41 (31) |
| Hypertension       |       | 0.549   |          |         | 0.082   |          |         |
| No                 | 32 (24) | 15 (11) | 17 (13) | 0.21 (16) | 11 (8) | 0.22 (11) | 0.22 (11) |
| Yes                | 102 (76) | 54 (40) | 48 (36) | 0.49 (37) | 53 (40) | 0.53 (40) | 0.53 (40) |
| Smoking status     |       | 0.178   |          |         | 0.716   |          |         |
| No                 | 44 (33) | 19 (14) | 25 (19) | 0.22 (16) | 22 (16) | 0.22 (16) | 0.22 (16) |
| Yes                | 90 (67) | 50 (37) | 40 (30) | 0.48 (36) | 42 (31) | 0.42 (31) | 0.42 (31) |
| Statins            |       | 0.056   |          |         | 0.075   |          |         |
| No                 | 86 (64) | 39 (29) | 47 (35) | 0.40 (30) | 46 (34) | 0.46 (34) | 0.46 (34) |
| Yes                | 48 (36) | 30 (22) | 18 (13) | 0.48 (22) | 18 (13) | 0.48 (13) | 0.48 (13) |
| Antiplatletes      |       | 0.821   |          |         | 0.273   |          |         |
| No                 | 94 (70) | 49 (37) | 45 (34) | 0.52 (39) | 42 (31) | 0.52 (31) | 0.52 (31) |
| Yes                | 40 (30) | 20 (15) | 20 (15) | 0.18 (13) | 22 (16) | 0.22 (16) | 0.22 (16) |
| ACES               |       | 0.173   |          |         | 0.630   |          |         |
| No                 | 72 (54) | 41 (31) | 31 (23) | 0.39 (29) | 33 (25) | 0.39 (25) | 0.39 (25) |
| Yes                | 62 (46) | 28 (21) | 34 (25) | 0.31 (23) | 31 (23) | 0.31 (23) | 0.31 (23) |
| CAD                |       | 0.032   |          |         | 0.046   |          |         |
| No                 | 76 (57) | 33 (25) | 43 (32) | 0.34 (25) | 42 (31) | 0.42 (31) | 0.42 (31) |
| Yes                | 58 (43) | 36 (27) | 22 (16) | 0.36 (27) | 22 (16) | 0.22 (16) | 0.22 (16) |
Table 1 continued. Associations of PPAR-γ expression in macrophages and smooth muscle cells with medical history, risk factors and medication intake in patients with advanced carotid atherosclerosis lesions.

| Clinical variables | N=134 | PPAR-γ expression in macrophages | PPAR-γ expression in smooth muscle cells |
|--------------------|-------|----------------------------------|-----------------------------------------|
|                    |       | Low (%) | High (%) | p-value | Low (%) | High (%) | p-value |
| PAD                |       |         |          |         |         |          |         |
| No                 |       | 97 (72) | 47 (35)  | 50 (37) | 49 (37) | 48 (36)  | 0.254   |
| Yes                |       | 37 (28) | 22 (16)  | 15 (11) | 21 (16) | 16 (12)  | 0.517   |
| CABG/PTCA          | 0.007 |         |          |         |         |          |         |
| No                 |       | 97 (72) | 43 (32)  | 54 (40) | 45 (34) | 52 (39)  |         |
| Yes                |       | 37 (28) | 26 (19)  | 11 (8)  | 25 (19) | 12 (9)   |         |
| Symptoms           | 0.504 |         |          |         |         |          |         |
| No                 |       | 62 (46) | 30 (22)  | 32 (24) | 27 (20) | 35 (26)  |         |
| Yes                |       | 72 (54) | 39 (29)  | 33 (25) | 43 (32) | 29 (22)  |         |

Table 2. Associations of RXR-α expression in macrophages and smooth muscle cells with medical history, risk factors and medication intake in patients with advanced carotid atherosclerosis lesions.

| Clinical variables | N=134 | RXR-α expression in macrophages | RXR-α expression in smooth muscle cells |
|--------------------|-------|----------------------------------|-----------------------------------------|
|                    |       | Low (%) | High (%) | p-value | Low (%) | High (%) | p-value |
| Age (mean ±SD)     | 71.02±7.98 | 70.98±7.67 | 70.90±8.28 | 0.966 | 70.61±8.51 | 71.29±7.38 | 0.846 |
| Gender             | 0.800 |         |          |         |         |          |         |
| Male               |       | 109 (81) | 51 (38)  | 58 (43) | 61 (46) | 48 (36)  |         |
| Female             |       | 25 (19)  | 11 (8)   | 14 (11) | 9 (7)   | 16 (12)  |         |
| Carotid            | 0.806 |         |          |         |         |          |         |
| Right              |       | 75 (56)  | 34 (25)  | 41 (31) | 40 (30) | 35 (26)  |         |
| Left               |       | 59 (44)  | 28 (21)  | 31 (23) | 30 (22) | 29 (22)  |         |
| Stenosis grade     | 0.165 |         |          |         |         |          |         |
| <90%               |       | 67 (50)  | 27 (20)  | 40 (30) | 28 (21) | 39 (29)  |         |
| ≥90%               |       | 67 (50)  | 35 (26)  | 32 (24) | 42 (31) | 25 (19)  |         |
| Diabetes           | 0.466 |         |          |         |         |          |         |
| No                 |       | 97 (72)  | 43 (32)  | 54 (40) | 51 (38) | 46 (34)  |         |
| Yes                |       | 37 (28)  | 19 (14)  | 18 (13) | 19 (14) | 18 (13)  |         |
| Hyperlipidemia     | 0.048 |         |          |         |         |          |         |
| No                 |       | 44 (33)  | 15 (11)  | 29 (22) | 19 (14) | 25 (19)  |         |
| Yes                |       | 90 (67)  | 47 (35)  | 43 (32) | 51 (38) | 39 (29)  |         |
| Hypertension       | 0.049 |         |          |         |         |          |         |
| No                 |       | 32 (24)  | 10 (7)   | 22 (16) | 16 (12) | 16 (12)  |         |
| Yes                |       | 102 (76) | 52 (39)  | 50 (37) | 54 (40) | 48 (36)  |         |
Carotid specimens' histopathology

The carotid plaque surgical specimens were collected intraoperatively immediately after endarterectomy and fixed in 10% buffered formalin for 24 hours. After decalcification, if necessary, specimens were embedded in paraffin wax using conventional techniques, cut transversely at 4 μm and stained with hematoxylin-eosin (H-E). After staining with H-E, 3 to 4 sections per specimen were examined. The section with plaque ulceration or thrombus, the most stenotic segment of the plaques, or both sections, were chosen for further analysis. Plaques were classified into 2 groups: (1) thrombotic plaques including (1a) plaque rupture, (1b) plaque erosion, and (1c) calcified nodule, and (2) plaques without acute thrombosis divided into: (2a) vulnerable and (2b) stable plaques [38].

Immunohistochemistry

Immunostainings for PPAR-γ and RXR-α were performed on paraffin-embedded carotid plaque surgical specimens using a commercially available mouse (IgG1) monoclonal antibody (E-8) that recognizes the carboxy terminus of human PPAR-γ (Santa Cruz Biochemicals, Santa Cruz, CA, USA), reacting with PPAR-γ1 and -γ2, and another rabbit polyclonal antibody that recognizes human RXR-α (D-20) (Santa Cruz Biochemicals). Briefly, 4 μm thick tissue sections were dewaxed in xylene and were brought to water through graded alcohols. To remove the endogenous peroxidase activity, sections were then treated with freshly prepared 0.3% hydrogen peroxide in methanol in the dark, for 30 min (minutes), at room temperature. Antigen retrieval was performed for PPAR-γ antigen detection, by

| Clinical variables | N=134 | RXR-α expression in macrophages | | RXR-α expression in smooth muscle cells | |
|-------------------|-------|---------------------------------|---|-----------------|---|
|                   |       | Low (%) | High (%) | p-value | Low (%) | High (%) | p-value |
| Smoking status    |       |         |         |         |         |         |         |
| No                | 44 (33) | 20 (15) | 24 (18) | 0.894 | 23 (17) | 21 (16) | 0.995 |
| Yes               | 90 (67) | 42 (31) | 48 (36) |         | 47 (35) | 43 (32) |         |
| Statins           |       |         |         |         |         |         |         |
| No                | 86 (64) | 41 (31) | 45 (34) | 0.662 | 46 (34) | 40 (30) | 0.698 |
| Yes               | 48 (36) | 21 (16) | 27 (20) |         | 24 (18) | 24 (18) |         |
| Antiplates        |       |         |         |         |         |         |         |
| No                | 94 (70) | 47 (35) | 47 (35) | 0.184 | 50 (37) | 44 (33) | 0.735 |
| Yes               | 40 (30) | 15 (11) | 25 (19) |         | 20 (15) | 20 (15) |         |
| ACEs              |       |         |         |         |         |         |         |
| No                | 72 (54) | 35 (26) | 37 (28) | 0.557 | 38 (28) | 34 (25) | 0.892 |
| Yes               | 62 (46) | 27 (20) | 35 (26) |         | 32 (24) | 30 (22) |         |
| PAD               |       |         |         |         |         |         |         |
| No                | 76 (57) | 33 (25) | 43 (32) | 0.449 | 38 (28) | 38 (28) | 0.552 |
| Yes               | 58 (43) | 29 (22) | 29 (22) |         | 32 (24) | 26 (19) |         |
| CABG/PTCA         |       |         |         |         |         |         |         |
| No                | 97 (72) | 44 (33) | 53 (40) | 0.732 | 50 (37) | 47 (35) | 0.795 |
| Yes               | 37 (28) | 18 (13) | 19 (14) |         | 20 (15) | 17 (13) |         |
| Symptoms          |       |         |         |         |         |         |         |
| No                | 62 (46) | 25 (19) | 37 (28) | 0.963 | 29 (22) | 33 (25) | 0.517 |
| Yes               | 72 (54) | 37 (28) | 35 (26) |         | 41 (31) | 31 (23) |         |

Table 2 continued. Associations of RXR-α expression in macrophages and smooth muscle cells with medical history, risk factors and medication intake in patients with advanced carotid atherosclerosis lesions.
Plasma C-Reactive Protein (CRP) levels were measured on the BN ProSpec nephelometer (Dade Behring, Siemens Healthcare Diagnostics) with fully automated latex particle-enhanced immunonephelometric assay, according to the manufacturer’s instructions. The intra- and inter-assay CVs were less than 6% and less than 7%, respectively.

Statistical analysis

The associations of PPAR-γ and RXR-α expression with clinical variables of medical history, risk factors and medication intake were assessed by chi-square test. Spearman’s rank correlation coefficient (R) was used to evaluate the linear relationships PPAR-γ and RXR-α expression. The inter-observer agreement was determined with the use of κ statistics. The κ value is indicated including the standard error (SE). A two-tailed p<0.05 was considered statistically significant. Statistical analysis was performed using the software package SPSS for Windows (version 11.0; SPSS Inc., Chicago, IL, USA).

RESULTS

One hundred and thirty-four patients were evaluated. Main characteristics of the patient population are depicted in Tables 1 and 2. The mean age was 71.02±7.98 years, and the vast majority (81%) were male. Seventy-two patients (54%) suffered from carotid atherosclerosis-related neurological event (amaurosis fugax or stroke or TIA). A thrombotic plaque was observed in 49 (37%) cases, 44 (33%) of which were ruptured. Of the remaining non-thrombotic plaques, 30 (22%) were classified as vulnerable. Thrombotic plaques were observed more frequently in patients affected by stroke, TIA or amaurosis fugax as compared to asymptomatic patients (p<0.001).

PPAR-γ positivity in macrophages and smooth muscle cells was noted in 84 (63%) and 95 (71%) out of 134 carotid specimens, respectively. RXR-α positivity in macrophages and smooth muscle cells was noted in 129 (96%) and 133 (99%) out of 134 carotid specimens, respectively. Representative immunostainings for PPAR-γ and RXR-α protein expression in macrophages and smooth muscle cells are depicted in Figures 1 and 2, respectively. The vast majority of carotid specimens did not show positive immunoreactivity for PPAR-γ and RXR-α in endothelial cells, as only 11 (8%) cases were PPAR-γ positive and only 13 (10%) cases were RXR-α positive (data not shown). The low incidence of PPAR-γ and RXR-α immunopositivity in endothelial cells did not permit any statistical analysis with clinical variables in this cellular population (data not shown).

Low PPAR-γ expression in macrophages was significantly more frequently observed in patients with history of CAD and CABB/PTCA (Table 1, p=0.032 and p=0.007, respectively). Accordingly, a significantly increased incidence of low PPAR-γ expression in smooth muscle cells of patients...
presenting history of CAD or CABG/PTCA was noted (Table 1, p=0.046 and p=0.028, respectively). Low PPAR-γ expression in macrophages and smooth muscle cells was also more frequently observed in patients receiving therapy with statins, without reaching statistical significance (Table 1, p=0.056 and p=0.075, respectively). An increased incidence of low PPAR-γ expression in smooth muscle cells was also noted in patients with no evidence of hypertension, without reaching statistical significance (Table 1, p=0.082).

Symptomatic patients more frequently showed low PPAR-γ expression in smooth muscle cells compared to asymptomatic patients, without reaching statistical significance (Table 1, p=0.061). When looking within specific cerebrovascular events, patients with amaurosis fugax more frequently presented low PPAR-γ expression in smooth muscle cells compared to asymptomatic patients, at a statistically significant level (p=0.008). PPAR-γ expression in smooth muscle cells was also significantly different between asymptomatic patients and those with combined amaurosis fugax/stroke (p=0.020), as well as amaurosis fugax/TIA (p=0.028).

A significantly increased frequency of low RXR-α expression in macrophages localized within carotid atherosclerotic lesions obtained from patients presenting history of hyperlipidemia was noted (Table 2, p=0.048). Hypertensive patients more frequently showed low RXR-α expression in macrophages compared to normotensive ones (Table 2, p=0.049). Patients presenting advanced carotid stenosis grade (≥90%) exhibited significantly increased incidence of low RXR-α expression in smooth muscle cells compared to those with carotid stenosis grade <90% (Table 2, p=0.015). Female patients more frequently presented high RXR-α expression in smooth muscle cells compared to males, without reaching statistical significance (Table 2, p=0.071).

We further statistically analyzed PPAR-γ and RXR-α expression in relation with patients’ plasma homocysteine and CRP levels. Patients presenting elevated plasma CRP levels were characterized by a significantly increased incidence of low PPAR-γ expression in macrophages (Table 3, p=0.038). PPAR-γ expression down-regulation in macrophages was also more frequently observed in patients with enhanced homocysteine levels, without reaching statistical significance (Table 3, p>0.005). PPAR-γ expression in smooth muscle cells, as well as RXR-α expression in both macrophages and smooth muscle cells did not show significant association with plasma homocysteine and CRP levels (Table 3, p>0.005).

Spearman’s correlation analysis was used to evaluate the linear relationship between PPAR-γ and RXR-α expression. PPAR-γ expression in macrophages was positively associated with RXR-α expression (R_s=0.213, p=0.017). Accordingly, a positive association between PPAR-γ and RXR-α expression in smooth muscle cells was also noted (R_s=0.225, p=0.011). No significant association between PPAR-γ and RXR-α expression in endothelial cells was obtained (R_s=0.032, p=0.698).

**Figure 1.** Representative immunostainings for PPAR-γ in (A). Macrophages and (B). Smooth muscle cells (original magnification ×400).

**Figure 2.** Representative immunostainings for RXR-α in (A). Macrophages and (B). Smooth muscle cell (original magnification ×400).
Carotid and cerebrovascular disease have major public health implications given the associated morbidity and mortality; however, the best treatment for this disease remains uncertain. Currently, carotid endarterectomy has proven useful in primary and secondary prevention of stroke episodes in respect to patients with advanced internal carotid artery stenosis [43,44]. However, a significant number of patients are considered at high risk for such surgical procedures and they therefore have relatively few treatment options [45,46].

In the last few years, PPAR-γ has been recognized as a crucial player in the pathogenesis of atherosclerosis and a promising therapeutic target for the treatment of cardiovascular complications [47]. In fact, TZDs treatment was shown to attenuate the progression of carotid artery intima/media thickness, a well-described surrogate marker for cardiovascular risk [24,48]. TZD therapy in patients undergoing coronary stent implantation was also associated with less in-stent restenosis and repeated revascularization. Importantly, cardiovascular outcome studies further suggested that pioglitazone reduced all-cause mortality, myocardial infarction, and stroke in patients with type 2 diabetes [24,48]. Moreover, PPAR-γ expression was enhanced in neointima formed after balloon injury of rat endothelium, suggesting that PPAR-γ expression may be up-regulated in vascular cells when the vasculature is damaged [49]. At a cellular level, it has certainly been well-established that PPAR-γ is expressed in monocytes/macrophages, smooth muscle and endothelial cells localized within injured vascular wall [27,29,49,50]. Notably, PPAR-γ ligands were shown to exert beneficial effects on the control of macrophage lipid metabolism and inflammatory status, which play crucial roles in atherosclerosis development and progression [24–26]. Emerging evidence has also implicated PPAR-γ as an essential transcriptional modulator of smooth muscle cell proliferation [51–53].

In this aspect, the present study aimed to assess the immunohistochemical expression of PPAR-γ and RXR-α in different cellular populations localized within advanced atherosclerotic lesions obtained from patients that underwent carotid endarterectomy for vascular repair. We showed that the incidence of low PPAR-γ expression in macrophages and smooth muscle cells was significantly increased in patients with history of CAD and CABG/PTCA. Symptomatic patients (with amaurosis fugax alone or combined amaurosis fugax/stroke or amaurosis fugax/TIA) also more frequently presented low PPAR-γ expression in smooth muscle cells compared to asymptomatic patients. The reduced levels of PPAR-γ expression may be indicative of a more pronounced disease progression, raising the possibility that PPAR-γ may be involved in carotid atherosclerotic plaque stabilization. These findings may also suggest that PPAR-γ activation could be proved to be a more effective therapeutic intervention in patients at an early stage of disease. In this context, recent studies showed that PPAR-γ mRNA levels were significantly reduced in occlusive and ectatic atherosclerotic tissues compared to arterial control ones, which

| Clinical variables | N=123 | Homocysteine levels | p-value | CRP levels | p-value |
|-------------------|-------|---------------------|---------|------------|---------|
|                   |       | <24.18 µmol/L (%)   | ≥24.18 µmol/L (%) |       | <2.68 mg/L (%) | ≥2.68 mg/L (%) |
| PPAR-γ expression |       |                     |         |            |         |
| macrophages       |       | 60 (49)             | 63 (51) | 61 (50)    | 62 (50) |
| Low (%)           |       | 64 (52)             | 28 (23) | 36 (29)    | 26 (21) |
| High (%)          |       | 59 (44)             | 32 (26) | 27 (22)    | 35 (28) |
| PPAR-γ expression |       | 0.245               |         | 0.038      |         |
| smooth muscle cells|      |                      |         |            |         |
| Low (%)           |       | 66 (54)             | 32 (26) | 34 (28)    | 29 (24) |
| High (%)          |       | 57 (46)             | 28 (23) | 29 (24)    | 32 (26) |
| RXR-α expression |       | 0.943               |         | 0.242      |         |
| macrophages       |       | 0.537               |         | 0.419      |         |
| Low (%)           |       | 58 (47)             | 30 (24) | 28 (23)    | 31 (25) |
| High (%)          |       | 65 (53)             | 30 (24) | 35 (28)    | 30 (24) |
| RXR-α expression |       | 0.310               |         | 0.791      |         |
| smooth muscle cells|      |                      |         |            |         |
| Low (%)           |       | 66 (54)             | 35 (28) | 31 (25)    | 32 (26) |
| High (%)          |       | 57 (46)             | 25 (20) | 32 (26)    | 29 (24) |

**DISCUSSION**

Carotid and cerebrovascular disease have major public health implications given the associated morbidity and mortality; however, the best treatment for this disease remains uncertain. Currently, carotid endarterectomy has proven useful in primary and secondary prevention of stroke episodes in respect to patients with advanced internal carotid artery stenosis [43,44]. However, a significant number of patients are considered at high risk for such surgical procedures and they therefore have relatively few treatment options [45,46].

In the last few years, PPAR-γ has been recognized as a crucial player in the pathogenesis of atherosclerosis and a promising therapeutic target for the treatment of cardiovascular complications [47]. In fact, TZDs treatment was shown to attenuate the progression of carotid artery intima/media thickness, a well-described surrogate marker for cardiovascular risk [24,48]. TZD therapy in patients undergoing coronary stent implantation was also associated with less in-stent restenosis and repeated revascularization. Importantly, cardiovascular outcome studies further suggested that pioglitazone reduced all-cause mortality, myocardial infarction, and stroke in patients with type 2 diabetes [24,48]. Moreover, PPAR-γ expression was enhanced in neointima formed after balloon injury of rat endothelium, suggesting that PPAR-γ expression may be up-regulated in vascular cells when the vasculature is damaged [49]. At a cellular level, it has certainly been well-established that PPAR-γ is expressed in monocytes/macrophages, smooth muscle and endothelial cells localized within injured vascular wall [27,29,49,50]. Notably, PPAR-γ ligands were shown to exert beneficial effects on the control of macrophage lipid metabolism and inflammatory status, which play crucial roles in atherosclerosis development and progression [24–26]. Emerging evidence has also implicated PPAR-γ as an essential transcriptional modulator of smooth muscle cell proliferation [51–53].

In this aspect, the present study aimed to assess the immunohistochemical expression of PPAR-γ and RXR-α in different cellular populations localized within advanced atherosclerotic lesions obtained from patients that underwent carotid endarterectomy for vascular repair. We showed that the incidence of low PPAR-γ expression in macrophages and smooth muscle cells was significantly increased in patients with history of CAD and CABG/PTCA. Symptomatic patients (with amaurosis fugax alone or combined amaurosis fugax/stroke or amaurosis fugax/TIA) also more frequently presented low PPAR-γ expression in smooth muscle cells compared to asymptomatic patients. The reduced levels of PPAR-γ expression may be indicative of a more pronounced disease progression, raising the possibility that PPAR-γ may be involved in carotid atherosclerotic plaque stabilization. These findings may also suggest that PPAR-γ activation could be proved to be a more effective therapeutic intervention in patients at an early stage of disease. In this context, recent studies showed that PPAR-γ mRNA levels were significantly reduced in occlusive and ectatic atherosclerotic tissues compared to arterial control ones, which
was ascribed to the increased amount of cytokines in the plaque microenvironment [54]. Moreover, PPARγ1 expression in carotid atheromas was not down-regulated in any diabetic symptomatic patients compared to asymptomatic ones [55]. Such association was not obtained in diabetic patients, raising the possibility that certain clinical factors may affect the impact of PPARγ in the pathogenesis of atherosclerosis [55]. Notably, PPARγ 12Ala allele carriers were shown to have less widespread CAD, being also considerably protected against 10-year cardiovascular morbidity and mortality [56]. These long-term findings in patients with manifest CAD further supported an important role for PPARγ in determining vascular risk. We further found a significant association between PPARγ expression in macrophages and plasma CRP levels, which may suggest a possible interlink between carotid atherosclerosis, PPARγ and inflammatory infiltration associated with carotid plaque destabilization and subsequent neurologic events. In support of this view, several convincing pieces of evidence have implied a crucial role for PPARγ in certain inflammatory pathways related with atherosclerosis progression [25,26].

Accordingly, we showed that RXR-α expression down-regulation was associated with pronounced disease progression in patients with advanced atherosclerotic lesions. In fact, the incidence of low RXR-α expression in macrophages was significantly increased in patients with evidence of hyperlipidemia and hypertension. Patients with advanced carotid stenosis grade also presented significant increased frequency of low RXR-α expression in smooth muscle cells. In this context, several substantial studies have revealed that RXR may be involved in the pathogenesis of atherosclerosis. More to the point, RXRs have been identified as important regulators of glucose, fatty acid and cholesterol metabolism, which are associated with common metabolic disorders such as diabetes type 2, hyperlipidaemia and atherosclerosis [57]. RXR activation by bexarotene was shown to modulate essential metabolic pathways governing atherosclerosis in mice by improving, at least in part, the circulating cholesterol distribution profile [58]. RXR activation also considerably reduced the development of atherosclerosis in apolipoprotein E-/- mice [59]. Moreover, RXR agonists inhibited phorbol-12-myristate-13-acetate (PMA)-induced monocyteic TPH-1 cell differentiation into macrophage-like cells [60]. Notably, simultaneous PPARγ and RXR activation suppressed foam cell formation through enhanced cholesterol efflux despite the increased oxidized low density lipoprotein (oxLDL) uptake [61].

We further revealed that PPARγ expression in macrophages and smooth muscle cells was significantly associated with RXR-α expression. In this context, it should be noted that PPARγ forms heterodimers with RXRs in order to exert its function by regulating gene transcription or transrepresion. Remarkably, RXR-α activation by 9-cis-retinoic acid (RA) synergistically enhanced the inhibition of human coronary artery vascular smooth muscle cell growth induced by PPARγ activation [62]. Thus, dimerization of PPARγ with RXR-α was required to achieve maximal suppression of coronary artery vascular smooth muscle cell growth [62]. An increased incidence of low PPARγ expression in macrophages and smooth muscle cells was also noted in patients receiving lipid-lowering therapy with statins. This could be ascribed to the fact that this patients’ subgroup had already experienced more pronounced disease progression, such as hyperlipidemia, evidence of CABC/PTCA and elevated plasma homocysteine levels in order to receive therapy with statins.

**Conclusions**

PPARγ and RXR-α immunohistochemical expression was assessed for the first time in patients with advanced carotid atherosclerotic lesions who underwent carotid endarterectomy for vascular repair and was associated with important clinicopathological parameters, such as patients’ medical history, risk factors and medication intake. Low levels of PPARγ and RXR-α expression in both macrophages and smooth muscle cells were associated with a more pronounced disease progression in patients with advanced carotid atherosclerotic lesions. However, further research conducted on distinct patients’ groups (e.g., only diabetic or non-diabetic patients, only symptomatic or asymptomatic patients, only patients with or without evidence of CAD) is required to delineate the clinical implications of PPARγ and RXR-α in advanced stages of carotid atherosclerosis.

**Conflict of interest**

No conflict of interest.

**References:**

1. Hansson GK: Inflammatory mechanisms in atherosclerosis. J Thromb Haemost, 2006; 1: 328–31
2. Bonora E: The metabolic syndrome and cardiovascular disease. Ann Med, 2006; 38: 64–80
3. Tzotomalous K, Athyros VG, Karagiannis A, Mikhailidis DP: Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention? Expert Opin Ther Targets, 2008; 12: 809–20
4. Niesner A, Goronzy JJ, Weyand CM: Immune-mediated mechanisms in atherosclerosis: prevention and treatment of clinical manifestations. Curr Pharm Des, 2007; 13: 3701–10
5. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation, 2002; 105: 1135–43
6. Spagnoli LG, Bonanno E, Sangiorgi G, Mauriello A: Role of inflammation in atherosclerosis. J Nucl Med, 2007; 48: 1800–15
7. Mallika V, Goswami B, Rajappa M: Atherosclerosis pathophysiology and the role of novel risk factors: a clinobioclinical perspective. Angiology, 2007; 58: 313–22
8. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev, 1999; 20: 649–88
9. Holte RT, Wisely GB, Westin S et al: Ligand binding and co-activator assembly of the peroxisome proliferators activated receptor-γ. Nature, 1998; 395: 137–43
10. Hamza MS, Pott S, Vega VB et al: De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis. PLoS One 2009; 4: e9607
11. Germain P, Chambon P, Eichele G et al: International Union of Pharmacology. LXIII Retinoid X Receptors. Pharmacol Rev, 2006; 58: 760–72
12. Scanto A, Narkar V, Shen Q et al: Retinoid X receptors: Xploring their (patho)physiological functions. Cell Death Differ, 2004; 11: S126–43
13. Zoete V, Girodier A, Michielin O: Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta, 2007; 1771: 915–25
14. Feige JN, Gelman L, Michalik L et al: From: molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res, 2006; 45: 120–59
15. Sugden MC, Zarzaga MG, Holmes MJ: PPARs and the orchestration of metabolic fuel selection. Pharmacol Rev, 2009; 60: 141–50
60. Zhou L, Shen LH, Hu LH et al: Retinoid X receptor agonists inhibit phorbol-12-myristate-13-acetate (PMA)-induced differentiation of monocytic THP-1 cells into macrophages. Mol Cell Biochem, 2010; 335(1–2): 283–89

61. Argmann CA, Sanyez CG, McNeil CJ et al: Activation of peroxisome proliferator-activated receptor gamma and retinoid X receptor results in net depletion of cellular cholesteryl esters in macrophages exposed to oxidized lipoproteins. Arterioscler Thromb Vasc Biol, 2003; 23: 475–82

62. Benson S, Padmanabhan S, Kurtz TW, Pershadsingh HA: Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor-alpha exert synergistic antiproliferative effects on human coronary artery smooth muscle cells. Mol Cell Biol Res Commun, 2000; 3: 159–64